Inactivated Vibrio cholerae Strains That Express TcpA via the toxT -139F Allele Induce Antibody Responses against TcpA
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Cholera remains a major global public health problem, for which oral cholera vaccines (OCVs) being a valuable strategy. Patients, who have recovered from cholera, develop antibody responses against LPS, cholera toxin (CT), toxin-coregulated pilus (TCP) major subunit A (TcpA) and other antigens; thus, these responses are potentially important contributors to immunity against Vibrio cholerae infection. However, assessments of the efficacy of current OCVs, especially inactivated OCVs, have focused primarily on O-antigen-specific antibody responses, suggesting that more sophisticated strategies are required for inactivated OCVs to induce immune responses against TCP, CT, and other antigens. Previously, we have shown that the toxT-139F allele enables V. cholerae strains to produce CT and TCP under simple laboratory culture conditions. Thus, we hypothesized that V. cholerae strains that express TCP via the toxT-139F allele induce TCP-specific antibody responses. As anticipated, V. cholerae strains that expressed TCP through the toxT-139F allele elicited antibody responses against TCP when the inactivated bacteria were delivered via a mouse model. We have further developed TCP-expressing V. cholerae strains that have been used in inactivated OCVs and shown that they effect an antibody response against TcpA in vivo, suggesting that V. cholerae strains with the toxT-139F allele are excellent candidates for cholera vaccines.
Abstract
Cholera remains a major global public health problem, for which oral cholera vaccines (OCVs) being a valuable strategy. Patients, who have recovered from cholera, develop antibody responses against LPS, cholera toxin (CT), toxin-coregulated pilus (TCP) major subunit A (TcpA) and other antigens; thus, these responses are potentially important contributors to immunity against Vibrio cholerae infection. However, assessments of the efficacy of current OCVs, especially inactivated OCVs, have focused primarily on O-antigen-specific antibody responses, suggesting that more sophisticated strategies are required for inactivated OCVs to induce immune responses against TCP, CT, and other antigens. Previously, we have shown that the toxT-139F allele enables V. cholerae strains to produce CT and TCP under simple laboratory culture conditions. Thus, we hypothesized that V. cholerae strains that express TCP via the toxT-139F allele induce TCP-specific antibody responses. As anticipated, V. cholerae strains that expressed TCP through the toxT-139F allele elicited antibody responses against TCP when the inactivated bacteria were delivered via a mouse model. We have further developed TCP-expressing V. cholerae strains that have been used in inactivated OCVs and shown that they effect an antibody response against TcpA in vivo, suggesting that V. cholerae strains with the toxT-139F allele are excellent candidates for cholera vaccines.
참고문헌 (46)
- Clemens JD, "Cholera", Lancet, 390, pp.1539~1549 (2017)
- Koch R, "An address on cholera and its Bacillus", Br. Med. J, 2, pp.453~459 (1884)
- J B Kaper, "Cholera", Clinical Microbiology Reviews, 8(1), pp.48~86 (1995), American Society for Microbiology[DOI]
- Mutreja A, "Evidence for several waves of global transmission in the seventh cholera pandemic", Nature, 477, pp.462~465 (2011)
- Safa A, "Evolution of new variants of Vibrio cholerae O1", Trends Microbiol, 18, pp.46~54 (2010)
- Kim EJ, "Whole-genome sequence comparisons reveal the evolution of Vibrio cholerae O1", Trends Microbiol, 23, pp.479~489 (2015)
- Herrington DA, "Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans", J. Exp. Med, 168, pp.1487~1492 (1988)
- Lim MS, "Vibrio cholerae El Tor TcpA crystal structure and mechanism for pilus-mediated microcolony formation", Mol. Microbiol, 77, pp.755~770 (2010)
- Krebs SJ, "Protection and attachment of Vibrio cholerae mediated by the toxin-coregulated pilus in the infant mouse model", J. Bacteriol, 193, pp.5260~5270 (2011)
- Waldor MK, "Lysogenic conversion by a filamentous phage encoding cholera toxin", Science, 272, pp.1910~1914 (1996)
- Juliana Li, "Vibrio cholerae Toxin-Coregulated Pilus Structure Analyzed by Hydrogen", Deuterium Exchange Mass Spectrometry, 2008, pp.16(1), 137~148[DOI]
- Iredell JR, "Biotype-specific tcpA genes in Vibrio cholerae", FEMS Microbiol. Lett, 121, pp.47~54 (1994)
- Chin CS, "The origin of the Haitian cholera outbreak strain", N. Engl. J. Med, 364, pp.33~42 (2011)
- Ghosh P, "Haitian variant tcpA in Vibrio cholerae O1 El Tor strains in Kolkata, India", J. Clin. Microbiol, 52, pp.1020~1021 (2014)
- Cheney L, "Multilevel genome typing describes short-and long-term Vibrio cholerae molecular epidemiology", mSystems, 6, pp.e0013421~ (2021)
- Shaikh H, "Current and future cholera vaccines", Vaccine, 38(1), pp.118~126 (2020)
- Ali M, "Natural cholera infection-derived immunity in an endemic setting", J. Infect. Dis, 204, pp.912~918 (2011)
- Harris AM, "Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh", Infect. Immun, 77, pp.3850~3856 (2009)
- Charles RC, "Plasma and mucosal immunoglobulin M, immunoglobulin A, and immunoglobulin G responses to the Vibrio cholerae O1 protein immunome in adults with cholera in Bangladesh", J. Infect. Dis, 216, pp.125~134 (2017)
- Kauffman RC, "Single-cell analysis of the plasmablast response to Vibrio cholerae demonstrates expansion of cross-reactive memory B cells", mBio, 7, pp.e02021~16 (2016)
- Lopez AL, "Killed oral cholera vaccines : history, development and implementation challenges", Ther. Adv. Vaccines, 2, pp.123~136 (2014)
- Holmgren J, "An update on cholera immunity and current and future cholera vaccines", Trop. Med. Infect. Dis, 6, pp.64~ (2021)
- McCarty JM, "Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45", Vaccine, 36, pp.833~840 (2018)
- Levine MM, "Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR", Lancet, 2, pp.467~470 (1988)
- Aktar A, "Plasma and memory B cell responses targeting O-specific polysaccharide(OSP)are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh", PLoS Negl. Trop. Dis, 12, pp.e0006399~ (2018)
- Islam K, "Anti-O-specific polysaccharide(OSP)immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers", PLoS Negl. Trop. Dis, 12, pp.e0006376~ (2018)
- Mayo-Smith LM, "The live attenuated cholera vaccine CVD 103-HgR primes responses to the toxin-coregulated pilus antigen TcpA in subjects challenged with wild-type Vibrio cholerae", Clin. Vaccine Immunol, 24, pp.e00470~16 (2017)
- Rollenhagen JE, "Transcutaneous immunization with toxincoregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice", Infect. Immun, 74, pp.5834~5839 (2006)
- Asaduzzaman M, "The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1and O139", Infect. Immun, 72, pp.4448~4454 (2004)
- Taylor RK, "A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structure", Infect. Immun, 72, pp.6050~6060 (2004)
- Yu RR, "Regulation of gene expression in Vibrio cholerae by ToxT involves both antirepression and RNA polymerase stimulation", Mol. Microbiol, 43, pp.119~134 (2002)
- Sanchez J, "Expression of cholera toxin under non-AKI conditions in Vibrio cholerae El Tor induced by increasing the exposed surface of cultures", J. Bacteriol, 186, pp.1355~1361 (2004)
- Cobaxin M, "Cholera toxin expression by El Tor Vibrio cholerae in shallow culture growth conditions", Microb. Pathog, 66, pp.5~13 (2014)
- Jonson G, "Expression of virulence factors by classical and El Tor Vibrio cholerae in vivo and in vitro", FEMS Microbiol. Lett, 74, pp.221~228 (1990)
- Iwanaga M, "Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor", Microbiol. Immunol, 30, pp.1075~1083 (1986)
- Lee D, "Alterations in glucose metabolism in Vibrio cholerae serogroup O1 El Tor biotype strains", Sci. Rep, 10, pp.308~ (2020)
- Baek Y, "Cholera toxin production in Vibrio cholerae O1 El Tor biotype strains in single-phase culture", Front. Microbiol, 11, pp.825~ (2020)
- Kim EJ, "Replication of Vibrio cholerae classical CTX phage", Proc. Natl. Acad. Sci. USA, 114, pp.2343~2348 (2017)
- Dominique Legros, "Global Cholera Epidemiology: Opportunities to Reduce the Burden of Cholera by 2030", The Journal of Infectious Diseases, 218(suppl_3), pp.S137~S140 (2018), Oxford University Press (OUP)[DOI]
- Harris JB, "Cholera : Immunity and prospects in vaccine development", J. Infect. Dis, 218, pp.141~146 (2018)
- Teoh SL, "Global economic evaluation of oral cholera vaccine : A systematic review", Hum. vaccin. Immunother, 14, pp.420~429 (2018)
- Hauke CA, "Production of putative enhanced oral cholera vaccine strains that express toxin-coregulated pilus", PLoS One, 12, pp.e0175170~ (2017)
- Zareitaher T, "Immunogenic efficacy of DNA and protein-based vaccine from a chimeric gene consisting OmpW, TcpA and CtxB of Vibrio cholerae", Immunobiology, 227, pp.152190~ (2022)
- Sharma MK, "Expression of toxin co-regulated pilus subunit A(TcpA)of Vibrio cholerae and its immunogenic epitopes fused to cholera toxin B subunit in transgenic tomato(Solanum lycopersicum)", Plant Cell Rep, 27, pp.307~318 (2008)
- Sit B, "Animal models for dissecting Vibrio cholerae intestinal pathogenesis and immunity", Curr. Opin. Microbiol, 65, pp.1~7 (2022)
- Heidelberg JF, "DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae", Nature, 406, pp.477~483 (2000)